Dronabinol Market to Hit USD 6.84 Billion by 2032, Growing at 9.1% CAGR Dronabinol, the synthetic delta-9-THC formulation, has gained significant traction in pharmaceutical applications, particularly for chemotherapy-induced nausea and HIV-related anorexia. Its versatility in addressing multiple therapeutic areas has positioned it as a valuable alternative to traditional medications, especially amid growing concerns about opioid dependence. The market's momentum is further reinforced by technological advancements in drug delivery systems and increasing patient awareness about cannabinoid therapies. Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/155136/global-dronabinol-market